TABLE 2.
Cumulative MIC distributions for ceftazidime and ceftazidime-avibactam against 7,062 clinical isolates of P. aeruginosa in 2012 to 2014 in four geographic regions
| Isolate type or region (no. of isolates) | Antimicrobial agent | No. (cumulative %) of isolates inhibited at an MIC (μg/ml) ofa: |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ≤0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | >128 | ||
| All isolates (7,062) | Ceftazidime | 93 (1.3) | 606 (9.9) | 2,805 (49.6) | 1,295 (68.0) | 636 (77.0) | 320 (81.5) | 479 (88.3) | 452 (94.7) | 190 (97.4) | 186 (100) |
| Ceftazidime-avibactam | 167 (2.4) | 1,178 (19.0) | 3,241 (64.9) | 1,159 (81.4) | 754 (92.0) | 176 (94.5) | 163 (96.8) | 115 (98.5) | 47 (99.1) | 62 (100) | |
| MBLb negative (6,756)c | Ceftazidime | 93 (1.4) | 606 (10.3) | 2,803 (51.8) | 1,295 (71.0) | 630 (80.3) | 285 (84.5) | 390 (90.3) | 364 (95.7) | 163 (98.1) | 127 (100) |
| Ceftazidime-avibactam | 167(2.5) | 1,178 (19.9) | 3,238 (67.8) | 1,159 (85.0) | 742 (96.0) | 130 (97.9) | 68 (98.9) | 43 (99.5) | 15 (99.8) | 16 (100) | |
| Europe (3,893) | Ceftazidime | 60 (1.5) | 361 (10.8) | 1,542 (50.4) | 711 (68.7) | 339 (77.4) | 178 (82.0) | 272 (89.0) | 255 (95.5) | 94 (97.9) | 81 (100) |
| Ceftazidime-avibactam | 106 (2.7) | 710 (21.0) | 1,759 (66.1) | 635 (82.5) | 395 (92.6) | 99 (95.1) | 92 (97.5) | 58 (99.0) | 18 (99.5) | 21 (100) | |
| Asia/South Pacific (1,392) | Ceftazidime | 16 (1.1) | 102 (8.5) | 591 (50.9) | 251 (69.0) | 127 (78.1) | 51 (81.8) | 79 (87.4) | 84 (93.5) | 38 (96.2) | 53 (100) |
| Ceftazidime-avibactam | 32 (2.3) | 208 (17.2) | 691 (66.9) | 218 (82.5) | 148 (93.2) | 17 (94.4) | 12 (95.3) | 21 (96.8) | 17 (98.0) | 28 (100) | |
| Latin America (1,088) | Ceftazidime | 13 (1.2) | 86 (9.1) | 392 (45.1) | 190 (62.6) | 97 (71.5) | 70 (77.9) | 85 (85.8) | 70 (92.2) | 38 (95.7) | 47 (100) |
| Ceftazidime-avibactam | 20 (1.8) | 156 (16.2) | 469 (59.3) | 175 (75.4) | 145 (88.7) | 47 (93.0) | 43 (97.0) | 17 (98.5) | 6 (99.1) | 10 (100) | |
| Middle East/Africa (689) | Ceftazidime | 4 (0.6) | 57 (8.9) | 280 (49.5) | 143 (70.2) | 73 (80.8) | 21 (83.9) | 43 (90.1) | 43 (96.4) | 20 (99.3) | 5 (100) |
| Ceftazidime-avibactam | 9 (1.3) | 104 (16.4) | 322 (63.1) | 131 (82.1) | 66 (91.7) | 13 (93.6) | 16 (95.9) | 19 (98.7) | 6 (99.6) | 3 (100) | |
a
MIC90s are in bold.
b
MBL, metallo-β-lactamase.
c
This isolate type includes carbapenem-sensitive and carbapenem-nonsusceptible metallo-β-lactamase-negative isolates.